<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339166</url>
  </required_header>
  <id_info>
    <org_study_id>ESNi-PGT</org_study_id>
    <nct_id>NCT04339166</nct_id>
  </id_info>
  <brief_title>Embryo Selection by Noninvasive Preimplantation Genetic Test</brief_title>
  <acronym>ESNi-PGT</acronym>
  <official_title>A Multicenter Clinical Study on Embryo Selection by Using the Ploidy of Cell Free DNA in Embryo Culture Medium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jinling Hospital,Nanjing University,School Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Maternity and Reproductive hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwest Women's and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Medical Center of Chinese People's Liberation Army General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yikon Genomics Company, Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Second Hospital of Sichuan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to explore whether non-invasive chromosome screening (NICS)&#xD;
      can be used as an effective indicator for embryos selection besides morphology through a&#xD;
      multicenter randomized controlled trial, by comparing the differences of live birth rate,&#xD;
      pregnancy rate and miscarriage rate between the two groups of embryo selection by &quot;NICS+&#xD;
      morphology&quot; and embryo selection only by &quot;morphology&quot; in IVF cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chromosomal abnormalities commonly exist in early human embryos, and often cause embryo&#xD;
      implantation failure and pregnancy loss in in-vitro fertilization (IVF) treatments.&#xD;
      Preimplantation genetic testing for aneuploidies (PGT-A) by comprehensive chromosome&#xD;
      screening (CCS) has been widely applied in IVF practices to select embryos with normal&#xD;
      ploidy. Although multiple clinical trials have demonstrated improved clinical outcomes with&#xD;
      PGT-A, it's in controversial for whether PGT-A is truly worthwhile to be offered to all IVF&#xD;
      patients. One of the main concerns is that it involves an embryo biopsy procedure, which is&#xD;
      invasive and the long-term safety issue of the embryo biopsy remains to be fully&#xD;
      investigated.&#xD;
&#xD;
      In recent years, researchers have found that the spent medium of embryo culture contains&#xD;
      trace amount of cell-free DNA, which may reflect the ploidy of the embryo. The non-invasive&#xD;
      chromosome screening (NICS) approach utilizing spent culture medium samples has been&#xD;
      evaluated in studies. However, the clinical value of NICS as a new effective indicator to&#xD;
      evaluate embryo competence so far has not been justified by randomized clinical trials.&#xD;
&#xD;
      The main purpose of this project is to verify whether NICS can be used as a new effective&#xD;
      indicator for evaluating embryo developmental potential through multi-center, randomized&#xD;
      clinical trials&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks after the first embryo transfer</time_frame>
    <description>Number of women with ongoing pregnancies after the first transfer/ number of women randomized to the specific group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>7 weeks after the first embryo transfer</time_frame>
    <description>Number of women with clinical pregnancies after the first transfer / number of women randomized to the specific group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>28 weeks of after the first embryo transfer</time_frame>
    <description>Number of pregnancy losses / number of clinical pregnancies after the first transfer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>within 2 weeks after live birth</time_frame>
    <description>Number of women with live births after the first transfer / number of women randomized to the specific group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1148</enrollment>
  <condition>Infertility</condition>
  <condition>Chromosome Abnormality</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single thawed blastocyst transfer with blastocyst selection according to the analysis of NICS and morphologic score.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Single thawed blastocyst transfer with blastocyst selection according to morphologic score.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Non-invasive chromosome screening（NICS）</intervention_name>
    <description>NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infertile couples receiving IVF- ICSI procedure for assisted reproduction cycle&#xD;
&#xD;
          2. Female age: 35 - 42 years old&#xD;
&#xD;
          3. Women receiving controlled ovarian hyperstimulation treatment (including ultra-long&#xD;
             protocol、long-protocol 、short protocol treatment with GnRH agonist and GnRH antagonist&#xD;
             treatment protocol); and the number of oocytes ≥6; The female BMI is from 18 to&#xD;
             30kg/m2.&#xD;
&#xD;
          4. Culture embryos to blastocyst stage and all the blastocysts will be single&#xD;
             cryopreserved.&#xD;
&#xD;
          5. Single frozen-thawed blastocyst Transferred for the first time&#xD;
&#xD;
          6. The number of blastocysts ≥2, morphology grade (above 4BC/4CB)&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. One of couples with IVF or ICSI contraindications(such as poorly controlled type I or&#xD;
             type II diabetes; liver disease or dysfunction; kidney disease or renal function&#xD;
             abnormality; significant anemia; history of deep venous thrombosis, pulmonary embolus;&#xD;
             history of cerebrovascular accident; uncontrolled hypertension or diagnosed heart&#xD;
             disease; history of cervical, endometrial or breast cancer; undiagnosed vaginal&#xD;
             bleeding.)&#xD;
&#xD;
          2. PGT cycles&#xD;
&#xD;
          3. Women who have pathologies or malformations that affect the pregnancy outcome: genital&#xD;
             malformations, untreated hydrosalpinx, untreated uterine infections, intramural myomas&#xD;
             &gt; 4cm , benign tumor of pelvic and abdominal cavity&gt; 4cm, intimal thickness&lt;8mm,&#xD;
             pituitary tumors and malignant tumors of various tissues and organs during the&#xD;
             patient's participation in the study&#xD;
&#xD;
          4. Untreated hyperprolactinemia, thyroid disease, adrenal disease&#xD;
&#xD;
          5. Women with endometrial polyps that were not treated before embryo transfer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>IVF patients</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Qiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Qiao</last_name>
    <phone>010-82265080</phone>
    <email>jie.qiao@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yanwen xu, professor</last_name>
      <phone>020-87606345</phone>
      <email>xuyanwen@live.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiping Qian, professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guimin Hao, professor</last_name>
      <phone>0311-66002721</phone>
      <email>haoguimin@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei Maternity and Reproductive hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyi Cai</last_name>
      <phone>0311-82626066</phone>
      <email>cai760829@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yichun Guan, professor</last_name>
      <phone>0371-66903686</phone>
      <email>lisamayguan@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of Citic-Xiangya</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Hu</last_name>
      <phone>0731-82355100-8973</phone>
      <email>lianghu7@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinling Hospital,Nanjing University,School Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Yao</last_name>
      <phone>025-80860174</phone>
      <email>yaobing@nju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuxia Wang</last_name>
      <phone>024-9661540131</phone>
      <email>wangxxsj@sina.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Second Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Wang, professor</last_name>
      <phone>028-88570494</phone>
      <email>wangyy1210@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junzhao Zhao, professor</last_name>
      <phone>0577-88002304</phone>
      <email>z.joyce08@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Qiao</last_name>
      <phone>010-82265080</phone>
      <email>jie.qiao@263.net</email>
    </contact>
    <investigator>
      <last_name>Jie Qiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Medical Center of Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanqing Yao</last_name>
      <phone>010-66939258</phone>
      <email>yqyao@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest women's and children's hospital</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juanzi Shi</last_name>
      <phone>029-87219120</phone>
      <email>shijuanzi123@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Jie Qiao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Culture media</keyword>
  <keyword>Embryonic cell-free DNA</keyword>
  <keyword>Euploidy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

